Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

A toxicokinetic statement was drawn up.

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential
Absorption rate - oral (%):
Absorption rate - dermal (%):
Absorption rate - inhalation (%):

Additional information

The excerpt from the toxicokinetic statement is:

The concentration of L-valine in blood is relatively constant. For risk assessment purposes oral absorption of L-valine is set at 100%.


L-valine is of low volatility due to a very low vapour pressure (0.00000453 Pa). From this and from the particle size it is not expected that L-valine reaches the nasopharyncheal region or subsequently the tracheobronchial or pulmonary region.


However, being a very hydrophilic substance with a molecular mass of only 117.15, any L-valine reaching the lungs might be absorbed through aqueous pores. For risk assessment purposes, although it is unlikely that L-valine will be available to a high extent after inhalation via the lungs due to the low vapour pressure and high MMAD (Mass median aerodynamic diameter), the inhalation absorption of L-valine is set at 100%.

L-valine with high water solubility (88.5 g/L) and the log P value below 0 (-2.26) may be too hydrophilic to cross the lipid rich environment of the stratum corneum. Therefore, 10% dermal absorption of L-valine is proposed for risk assessment purposes.